Q3 2025 Fortis Healthcare Ltd Earnings Call Transcript
Key Points
- Fortis Healthcare Ltd (BOM:532843) reported a consolidated top line growth of 14.8% year-on-year, driven by a strong performance in the hospital business.
- The hospital business revenue increased by 16.8% to INR1,623 crores, contributing significantly to the overall revenue growth.
- Consolidated operating EBITDA increased by 32% to INR375 crores, with a margin improvement from 16.9% to 19.4%.
- Hospital occupancy improved to 67%, with a 6.2% increase in occupied beds, indicating better utilization of resources.
- The oncology specialty facility registered a growth of 30%, and neurosciences reported an 18% year-on-year growth, highlighting strong performance in key specialties.
- The diagnostic business showed a modest revenue growth of 3.5% year-on-year, indicating slower growth compared to the hospital segment.
- The Richmond Road facility incurred losses and was divested, reflecting challenges in maintaining profitability in certain locations.
- The Manyata Greenfield expansion is currently operating at a loss, with a break-even point expected by the first quarter of the next fiscal year.
- Legal costs are expected to remain high in the early part of the next year due to ongoing court cases.
- The diagnostic business is still adjusting to the impact of the Agilus rebranding exercise, which has involved significant marketing costs.
Ladies and gentlemen, good day and welcome to the Fortis Healthcare Ltd Q3 FY25 earnings conference call. (Operator Instructions). Please note that this conference is being recorded.
I now have the conference over to Mr. Anurag Kalra, Senior Vice President Investor Relations at Fortis Healthcare Limited. Thank you and over to you, sir.
Thank you very much. A very good afternoon and good evening, ladies and gentlemen, and thank you for taking the time to join us on our quarter three FY25 earnings call. The call is being chaired by our MD and CEO Dr. Ashutosh Raghuvanshi. With him we have our Chief Financial Officer, Mr. Vivek Goyel. From Agilus Diagnostics, we have Mr. Anand, the CEO of Agilus, as well as Akshay Tiwari, the CFO.
We will start with some opening comments by Dr. Raghuvanshi, post which Anand will take you through certain key highlights of the diagnosis and then we can open the floor for questions and answers.
Over to Dr. Raghuvanshi.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
